What the 2026 DEA Telehealth Extension Actually Means for Your Billing Operation

The DEA’s ongoing series of temporary extensions to Ryan Haight Act enforcement has created a billing environment that rewards practices with clean documentation protocols and punishes those operating on assumptions carried over from 2020 pandemic flexibilities. As of early 2026, the DEA’s telemedicine prescribing rules for Schedule III-V controlled substances remain under extended exemptions first introduced post-COVID, but the compliance clock is running. At Revenant Care Group, working across roughly 50 behavioral health practices, we see a consistent pattern: revenue leakage is not coming from the prescribing decision itself. It is coming from the billing and documentation layer that wraps it.

If your practice employs psychiatric nurse practitioners or psychiatrists who prescribe controlled substances via telehealth, specifically buprenorphine, stimulants for ADHD, or benzodiazepines, the intersection of DEA registration requirements, platform documentation, and CPT/modifier selection is where denial rates spike. We want to give you the tactical picture for 2026 so you can act before your next payer audit cycle.

The Ryan Haight Act and the DEA Extension: What Is Still in Effect in 2026

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 originally required an in-person medical evaluation before any Schedule II-V controlled substance could be prescribed via telemedicine. The COVID-19 public health emergency created a blanket exemption. The DEA has since issued a series of final and temporary rules that extend telehealth prescribing permissions for buprenorphine and other Schedule III-V substances through a registration framework that is still being finalized.

For 2026, the operative facts are these. The DEA proposed a Special Registration framework for telemedicine prescribing of controlled substances. That framework has not yet been fully implemented through final rulemaking as of mid-2026, and the most recent extension allows practitioners with a valid DEA registration in their state of practice to continue prescribing Schedule III-V substances via telemedicine without a prior in-person visit, provided specific platform and documentation standards are met. For Schedule II substances, the rules remain more restrictive and state-by-state variation applies. You should verify current DEA guidance directly at deadiversion.usdoj.gov and confirm with your state medical board, as enforcement posture varies by state.

The CPT and Modifier Configuration That Most Practices Are Getting Wrong

This is where we see the real dollar impact. A 10-provider psychiatric group seeing an average of 18 telehealth visits per provider per week is generating roughly 180 telehealth encounters weekly. If modifier and Place of Service code selection is incorrect on even 20 percent of those claims, at an average allowed amount of $175 per encounter for a 99213 or 99214, that is $6,300 in weekly exposure to denial or downcoding.

The correct configuration for a psychiatric telehealth visit billed to commercial payers and Medicare in 2026 is as follows:

• CPT codes: 99202-99215 for office-based E/M; 90792 for psychiatric diagnostic evaluation when appropriate; 90833, 90836, or 90838 as add-on psychotherapy codes when a licensed prescriber provides both medication management and psychotherapy in the same session
• Place of Service: POS 10 (Telehealth Provided in Patient’s Home) for patients receiving services at home; POS 02 (Telehealth Provided Other than in Patient’s Home) when the patient is at a non-home originating site
• Modifier 95: Appended to the primary E/M code to indicate synchronous telehealth delivery; required by most commercial payers
• Modifier GT: Still required by some Medicaid managed care plans despite Medicare’s migration to Modifier 95; confirm plan-by-plan
• Modifier 93: Audio-only telehealth, applicable where payers permit telephone-only psychiatric visits; reimbursement rates are typically 15-25 percent lower than video visits

When a practice is prescribing a controlled substance during a telehealth visit, the documentation must reflect the clinical basis for the prescription, the technology platform used, and confirmation that the prescribing practitioner held a valid DEA registration in the state where the patient was physically located at the time of service. Missing any one of these elements creates a recoverable overpayment exposure under a payer audit.

Revenue Impact by Practice Size: Where the Leakage Is Concentrated

We segment practices into three operational tiers when we assess billing performance. Here is what we typically see in 2026 across behavioral health groups with telehealth prescribing activity:

• Solo to 3-provider practices: Average annual telehealth denial rate of 18-24 percent on controlled substance-related encounters. Dollar impact runs $40,000-$85,000 in annual unrecovered revenue, primarily from POS code mismatches and missing modifier 95.
• 4 to 10-provider groups: Denial rates trend lower at 12-18 percent due to more structured billing workflows, but the absolute dollar leakage is larger: $120,000-$280,000 annually, often concentrated in 90792 undercoding and failure to bill add-on psychotherapy codes when clinically supported.
• 11 to 25-provider organizations: Payer-specific modifier and POS errors are the primary driver, compounded by multi-state DEA registration gaps when prescribers are licensed in multiple states. Annual exposure ranges from $300,000 to over $600,000 when Medicaid managed care plan-specific rules are not being tracked at the claim level.

Recovery percentages on corrected claims, when submitted within timely filing windows, average 68-74 percent of the originally denied amount across our client base. The window matters: most commercial payers allow 90-180 days from the original remittance date for corrected claim submission.

SUD Prescribing Visits and the Compounding Drug Screen Billing Gap

For practices operating at the intersection of psychiatric telehealth and substance use disorder treatment, particularly those prescribing buprenorphine via telehealth under the current DEA extension, there is a compounding revenue gap that most practices do not identify until an RCM audit surfaces it. Buprenorphine prescribing visits are typically accompanied by urine drug screening, and the coding on those screens is frequently wrong. We have written specifically about how most SUD practices are systematically undercoding G0480-G0483 drug screens and leaving 4-5 times the appropriate revenue per test on the table. If your telehealth prescribing practice includes any SUD patient population, read our full analysis here: G0480-G0483 Drug Screen Coding: Why Most SUD Practices Are Under-Coding.

Documentation Standards That Survive a Payer Audit in 2026

The single most actionable thing a behavioral health CFO can require before the next billing cycle is a documentation audit checklist appended to every telehealth prescribing note template. At minimum, the chart note for any controlled substance telehealth encounter must contain the following elements to survive commercial payer and Medicare audit scrutiny:

• Patient’s physical location at time of service (city and state), not just a checkbox confirming telehealth was used
• Prescriber’s DEA registration number and confirmation that the registration covers the patient’s state of location
• Video platform name and confirmation that the session was synchronous audio-video (not audio-only) when billing under Modifier 95
• Medical necessity statement that is substance-specific, not a generic controlled substance attestation
• Prescription details including drug, dose, days supply, and whether a PDMP query was performed where state law requires it

Payers conducting post-payment audits on controlled substance telehealth claims in 2026 are looking specifically for the first three elements listed above. When those are absent, recoupment demands follow. Mental health parity requirements under MHPAEA add another layer: if a payer is applying more restrictive documentation requirements to your psychiatric telehealth claims than they apply to equivalent medical telehealth services, that is a parity violation you can appeal. Our breakdown of MHPAEA parity appeals and the revenue recovery opportunity is here: Mental Health Parity Act Appeals: How Behavioral Health Practices Are Leaving Money on the Table.

What to Do Before the DEA Special Registration Framework Is Finalized

The DEA’s Special Registration process, once finalized, will likely require practitioners to affirmatively register for a telemedicine prescribing designation separate from their standard DEA registration. Practices should be tracking the DEA’s Federal Register notices and confirming that their credentialing and provider enrollment files will be updatable without creating billing gaps when the final rule takes effect. Work with your RCM team now to map every prescribing provider against the states where their patients are physically located during telehealth visits. Any state where you have active patient volume but no confirmed prescriber DEA registration for that state is a compliance and billing risk that needs resolution before the next payer contract renewal or audit cycle.

If you want a concrete look at where your practice stands on telehealth billing accuracy, modifier compliance, and denial recovery across your psychiatric or SUD prescribing visits, the Revenant Care Group team offers a free 30-day denial audit with no commitment required. We identify the specific CPT, modifier, and POS errors generating your current denial rate and give you a recovery projection before you decide whether to engage further. Schedule directly here: Book Your Free 30-Day Denial Audit.